CSIMarket
 


Iterum Therapeutics Plc  (ITRM)
Other Ticker:  
 
 

ITRM's Operating Income Growth by Quarter and Year

Iterum Therapeutics Plc's Operating Income results by quarter and year




ITRM Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -7.93 -6.83 -4.64
III Quarter September -16.69 -7.03 -4.87 -6.34
II Quarter June -10.82 -8.05 -6.99 -8.25
I Quarter March -8.53 -7.37 -5.85 -12.89
FY   -36.04 -30.38 -24.54 -32.12



ITRM Operating Income third quarter 2023 Y/Y Growth Comment
Iterum Therapeutics Plc in the third quarter 2023 recorded Operating Loss of $ -16.69 millions.

According to the results reported in the third quarter 2023, Iterum Therapeutics Plc achieved the best Operating Income growth in Major Pharmaceutical Preparations industry. While Iterum Therapeutics Plc' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2023.

Explain Operating Income growth


ITRM Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Iterum Therapeutics Plc's third quarter 2023 Operating Income $ -16.69 millions ITRM's Income Statement
Iterum Therapeutics Plc's third quarter 2022 Operating Income $ -7.03 millions Quarterly ITRM's Income Statement
New: More ITRM's historic Operating Income Growth >>


ITRM Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Iterum Therapeutics Plc's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ITRM's III. Quarter Q/Q Operating Income Comment
Recent results of -16.69 millions by Iterum Therapeutics Plc look even more unfavourable if you take a look at Operating Loss -10.82 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Iterum Therapeutics Plc achieved highest sequential Operating Income growth. While Iterum Therapeutics Plc's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ITRM's III. Quarter Q/Q Operating Income Comment
III. Quarter 2023 accomplishment of -16.69 millions by Iterum Therapeutics Plc come out even more unfavourable considering the Operating Loss -10.82 millions a quarter before.

Within Major Pharmaceutical Preparations industry Iterum Therapeutics Plc achieved highest sequential Operating Income growth. While Iterum Therapeutics Plc's Operating Income growth quarter on quarter, overall rank is .


Iterum Therapeutics Plc's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Operating Income 12 Months Ending $ -43.96 $ -34.31 $ -31.54 $ -30.38 $ -29.29
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Iterum Therapeutics Plc' has realized cumulative trailing twelve months Operating Loss of $ -44 millions in the Sep 30 2023 period.
The results are detiriorating as the cumulative Operating Loss is inflating from $ -34.31 millions in the twelve months ending a quarter before and $ -27.126 millions for the twelve months ending in the quarter a year ago Oliver  Wright mentioned.

Iterum Therapeutics Plc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Iterum Therapeutics Plc' has realized cumulative trailing twelve months Operating Loss of $ -44 millions in the Sep 30 2023 period.
The situation is getting worse as the cumulative Operating Loss is getting bigger from $ -34.31 millions in TTM ending quarter Jun 30 2023 and $ -27.126 millions for the twelve months ending in the quarter Sep 30 2022.

Iterum Therapeutics Plc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
ITRM's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for ITRM's Competitors
Operating Income Growth for Iterum Therapeutics Plc's Suppliers
Operating Income Growth for ITRM's Customers

You may also want to know
ITRM's Annual Growth Rates ITRM's Profitability Ratios ITRM's Asset Turnover Ratio ITRM's Dividend Growth
ITRM's Roe ITRM's Valuation Ratios ITRM's Financial Strength Ratios ITRM's Dividend Payout Ratio
ITRM's Roa ITRM's Inventory Turnover Ratio ITRM's Growth Rates ITRM's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Electromed Inc 222.73%$ 222.727 millions
National Healthcare Corp219.40%$ 219.397 millions
Amphastar Pharmaceuticals Inc 212.89%$ 212.890 millions
Viemed Healthcare Inc 186.32%$ 186.317 millions
Penumbra Inc 132.33%$ 132.333 millions
Alpha Pro Tech Ltd 119.94%$ 119.938 millions
Collegium Pharmaceutical Inc 119.93%$ 119.930 millions
Docgo Inc 107.37%$ 107.372 millions
Eli Lilly And Company104.32%$ 104.324 millions
Boston Scientific Corporation93.58%$ 93.575 millions
Pro dex Inc 92.95%$ 92.947 millions
Merit Medical Systems Inc88.33%$ 88.331 millions
Infusystem Holdings Inc79.96%$ 79.958 millions
Elite Pharmaceuticals Inc 78.10%$ 78.103 millions
Amneal Pharmaceuticals Inc 70.56%$ 70.559 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com